Fort Pitt Capital Group LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 3.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,364 shares of the company’s stock after buying an additional 748 shares during the quarter. Fort Pitt Capital Group LLC’s holdings in Johnson & Johnson were worth $2,907,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the period. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the period. FMR LLC lifted its position in shares of Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares during the period. Capital World Investors lifted its position in shares of Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after acquiring an additional 1,050,000 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock worth $2,363,788,000 after acquiring an additional 771,039 shares during the period. 65.70% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have commented on JNJ shares. Jefferies Group raised their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. UBS Group reiterated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research report on Saturday, September 30th. Cowen set a $147.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, October 6th. Citigroup raised their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective for the company in a research report on Wednesday, December 20th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $145.52.
Johnson & Johnson (JNJ) opened at $141.71 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $380,710.00, a P/E ratio of 24.60, a P/E/G ratio of 2.67 and a beta of 0.80. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $1.68 EPS. analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.37%. Johnson & Johnson’s dividend payout ratio is 58.33%.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Fort Pitt Capital Group LLC” was first reported by Equities Focus and is the property of of Equities Focus. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.equitiesfocus.com/2018/01/08/johnson-johnson-jnj-shares-bought-by-fort-pitt-capital-group-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.